For decades, biopharma executives have seen operational costs and complexities soar. As commercial pricing, reimbursement, and market access hurdles remain particularly difficult to overcome, CEOs are ...
As requested in Section 1544 of the FY2025 National Defense Authorization Act, a National Academies of Sciences, Engineering, and Medicine consensus study will conduct an "evaluation of alternative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results